Abstract:Introduction This analysis investigated the efficacy and safety of add-on lixisenatide by disease duration in Asian people with type 2 diabetes inadequately controlled with basal insulin ± oral antidiabetic drugs. Methods Data for Asian participants in the GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C studies were pooled and categorized by diabetes duration: < 10 years (group 1), 10 to < 15 years (group 2), and ≥ 15 years (group 3). Efficacy and safety of lixisenatide versus placebo were evaluated by subgroup. The potential influence of diabetes duration on efficacy was examined using multivariable regression analyses. Results A total of 555 participants were included (mean age 53.9 years, 52.4% male). No significant differences in treatment effect between the duration subgroups were observed for the changes from baseline to 24 weeks in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose (PPG), PPG excursion, body weight or body mass index, or the proportion of participants with HbA1c < 7% at 24 weeks (all P values for interaction > 0.1). Change in insulin dosage (U/day) was significantly different between subgroups ( P = 0.038). Multivariable regression analysis showed participants in group 1 had a smaller change in body weight and basal insulin dose over the 24-week treatment period than participants in group 3 ( P = 0.014 and 0.030, respectively) and were less likely to achieve an HbA1c < 7% than participants in group 2 ( P = 0.047). No severe hypoglycemia was reported. A higher proportion of participants in group 3 versus the other groups had symptomatic hypoglycemia, for both lixisenatide and placebo, and T2D duration had a significant effect on hypoglycemia risk ( P = 0.001). Conclusions Lixisenatide improved glycemic control in Asian individuals regardless of diabetes duration, without increasing the risk of hypoglycemia. Individuals with longer disease duration had a greater risk of symptomatic hypoglycemia than individuals with shorter disease duration regardless of treatment. No additional safety concerns were observed. Clinical Trial Registration GetGoal-Duo 1, ClinicalTrials.gov record NCT00975286; GetGoal-L, ClinicalTrials.gov record NCT00715624; GetGoal-L-C, ClinicalTrials.gov record NCT01632163.

The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan

Efficacy And Safety Of Lixisenatide In A Predominantly Asian Population With Type 2 Diabetes Insufficiently Controlled With Basal Insulin: The Getgoal-L-C Randomized Trial

PRISMA—efficacy and Safety of Lixisenatide for Type 2 Diabetes Mellitus

Lixisenatide Treatment Improves Glycaemic Control in Asian Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin with or Without Sulfonylurea: a Randomized, Double-Blind, Placebo-Controlled, 24-Week Trial (Getgoal-M-asia).

Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis

Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients

Efficacy and safety of lixisenatide in a predominantly <scp>A</scp> sian population with type 2 diabetes insufficiently controlled with basal insulin: <scp>T</scp> he <scp>GetGoal‐L‐C</scp> randomized trial

Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study

Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan

COMPARATIVE EFFICACY AND SAFETY OF LIXISENATIDE AND INSULIN REGIMENS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Efficacy of Once-Daily Glucagon-Like Peptide-1 Receptor Agonist Lixisenatide As an Add-on Treatment to Basal Insulin in Asian and White Adults with Type 2 Diabetes Mellitus: an Individual-Level Pooled Analysis of Phase III Studies

Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies

The research of the treatment to type 2 diabetes mellitus (T2DM) by lixisenatide

Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study

Effects of Age and Disease Duration on the Efficacy and Safety of Iglarlixi in Asian People with Type 2 Diabetes: A Post Hoc Analysis of the LixiLan-O-AP and LixiLan-L-CN Trials

The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

PDB59 LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS